Find information and the latest updates and background information on recent events related to a few of our key products.

Highlighting the Unmet Needs in Hidradenitis Suppurativa (HS)

Read more

Radioligand Therapy Supply Information

Read more

Updated packaging now available for SANDIMMUNE® 100 mg blister packages

Read more

Novartis Cosentyx® data at AAD VMX shows improvement in skin symptoms and quality of life was maintained up to one year in child

Read more

Novartis presents data at AAN on novel combination biomarker that may predict disability worsening in secondary progressive multiple sclerosis

Read more

Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS

Read more

Novartis Financial Results – Q3 2020

Read more

New policy related to the 340B program

Read more

AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy

Read more

Notice to Healthcare Providers and Entities

Read more

Novartis Financial Results – Q2 2020

Read more

Sandoz collaborates with Civica Rx to help reduce critical generic medicine shortages in US hospitals

Read more

Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation digital engagement technologies

Read more

Novartis Resolves Legacy FCPA Investigations

Read more

Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts

Read more

Standing for Racial Equity and Justice as One Novartis

Read more

AveXis joins AAVCOVID vaccine program from Massachusetts Eye and Ear and Massachusetts General Hospital

Read more

Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

Read more

Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative

Read more

Novartis completes safety review and initiates update to the Beovu® prescribing information worldwide

Learn more

Novartis donates 20,000 doses of hydroxychloroquine for COVID-19 PEP clinical trial

Learn more

Novartis is making a strong contribution to the fight against the COVID-19 pandemic

Read more

Novartis US response to COVID-19

Read more

Corrective Action for Certain 100-mg SANDIMMUNE® and NEORAL® Blister Packages in the US

Read more

Novartis provides update on use and safety of Beovu® in patients with wet AMD

Read more

Sandoz Resolves Generic Drug Antitrust Investigation in the U.S.

Read more

Form 483 posting by US Food and Drug Administration (FDA) – Novartis statement

Read more

Novartis statement on Zolgensma

Read more

The Novartis comment letter submitted July 16, 2018 to the Department of Health and Human Services (HHS) in response to the “HHS Blueprint to Lower Drug Prices and Reduce out-of-Pocket-Costs.”

Novartis response to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs

Novartis Pharmaceuticals Corporation (Novartis) Statement on Recall Outside the United States of Sandoz Generic Valsartan and Sandoz Valsartan and Hydrochlorothiazide Film-Coated Tablets

Read more